CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD.
Purpose: To know whether mild cognitive impairment (MCI) patients will develop Alzheimer's disease (AD) dementia in very short time or remain stable is of crucial importance, also considering new experimental drugs usually tested within very short time frames. Here we combined cerebrospinal fluid (C...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 13; pp. 3152 - 3165 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147137005&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 147137005 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: 2020 vid: 47 iid: 13 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 147137005 144055126 10.1007/s00259-020-04853-4 147137005 ppf: 3152 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD. aug: au: Santangelo, Roberto Masserini, Federico Agosta, Federica Sala, Arianna Caminiti, Silvia P. Cecchetti, Giordano Caso, Francesca Martinelli, Vittorio Pinto, Patrizia Passerini, Gabriella Perani, Daniela Magnani, Giuseppe Filippi, Massimo affil: Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy sug: ab: Purpose: To know whether mild cognitive impairment (MCI) patients will develop Alzheimer's disease (AD) dementia in very short time or remain stable is of crucial importance, also considering new experimental drugs usually tested within very short time frames. Here we combined cerebrospinal fluid (CSF) AD biomarkers and a neurodegeneration marker such as brain FDG-PET to define an objective algorithm, suitable not only to reliably detect MCI converters to AD dementia but also to predict timing of conversion. Methods: We included 77 consecutive MCI patients with neurological/neuropsychological assessment, brain 18F-FDG-PET and CSF analysis available at diagnosis and a neuropsychological/neurological evaluation every 6 months for a medium- to a long-term follow-up (at least 2 and up to 8 years). Binomial logistic regression models and Kaplan-Meier survival analyses were performed to determine the best biomarker (or combination of biomarkers) in detecting MCI converters to AD dementia and then, among the converters, those who converted in short time frames. Results: Thirty-five out of 77 MCI patients (45%) converted to AD dementia, with an average conversion time since MCI diagnosis of 26.07 months. CSF p-tau/Aβ42 was the most accurate predictor of conversion from MCI to AD dementia (82.9% sensitivity; 90% specificity). CSF p-tau/Aβ42 and FDG-PET-positive MCIs converted to AD dementia significantly earlier than the CSF-positive-only MCIs (median conversion time, 17.1 vs 31.3 months). Conclusions: CSF p-tau/Aβ42 ratio and brain FDG-PET may predict both occurrence and timing of MCI conversion to full-blown AD dementia. MCI patients with both biomarkers suggestive for AD will likely develop an AD dementia shortly, thus representing the ideal target for any new experimental drug requiring short periods to be tested for. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|